Shop By
Merchant Seal
Credit Cards
Credit Card Processing



  Home > PRESCRIPTION >

  Regu-Mate Solution, 1000 ml

Regu-Mate Solution, 1000 ml


 
Sold ONLY to licensed veterinarians and pharmacies. Submit license if not already on file. Fax :: 800-640-3274
Licensed Professional Price: $218.13
Rx:
Copy of License Required [No Prescriptions Please]

Stock Status:Currently Out of Stock

Availability: Usually Ships in 3 to 5 Business Days
Product Code: 15020
Qty:

Description
 

REGU-MATE SOLUTION

Oral Progestin

Regu-Mate (altrenogest) Solution 0.22% is indicated for the suppression of estrus in mares. Suppression of estrus allows for a predictable occurrence of estrus following drug withdrawal. This facilitates the attainment of regular cyclicity during the transition from winter anestrus to the physiological breeding season. Suppression of estrus will also facilitate management of prolonged estrus conditions. Suppression of estrus may be used to facilitate scheduled breeding during the physiological breeding season.

Regu-Mate Solution 0.22% produces a progestational effect in mares. It contains the active synthetic progestin - altrenogest.

Active Ingredients: Each ml of Regu-Mate (altrenogest) Solution 0.22% contains 2.2 mg of altrenogest in an oil solution.

Dosage and Administration:

While wearing protective gloves, administer orally at the rate of 1 mL per 110 pounds body weight (0.044 mg/kg) to be given one dose daily for 15 consecutive days. Administer directly on the posteriodorsal surface of the mare's tongue using a dose syringe or suitable plastic syringe. The drug may also be administered on the usual grain ration.

Dosage Schedule According To Mare's Approximate Weight:
770 lbs . . . 7 ml of Regu-Mate Solution
880 lbs . . . 8 ml
990 lbs . . . 9 ml
1100 lbs . . . 10 ml
1210 lbs . . . 11 ml
1320 lbs . . . 12 ml

Contraindications:
Regu-Mate (altrenogest) Solution 0.22% is contraindicated for use in mares having a previous or current history of uterine inflammation (i.e., acute, subacute, or chronic endometritis). Natural or synthetic gestagen therapy may exacerbate existing low-grade or smoldering uterine inflammation into a fulminating uterine infection in some instances.

Precautions:
Various synthetic progestins, including altrenogest, when administer to rats during the embryogenic stage of pregnancy at doses manyfold greater than the recommended equine dose caused fetal anomalies, specifically masculinization of the female genitalia.

WHICH MARES WILL RESPOND TO REGU-MATE (altrenogest) SOLUTION 0.22%: Extensive clinical trials have demonstrated that estrus will be suppressed in approximately 95% of the mares within three days; however, the post-treatment response depended on the level of ovarian activity when treatment was initiated. Estrus in mares exhibiting regular estrus cycles during the breeding season will be suppressed during treatment; these mares return to estrus four to five days following treatment and continue to cycle normally. Mares in winter anestrus with small follicles continued in anestrus and failed to exhibit normal estrus following withdrawal.

Response in mares in the transition phase between winter anestrus and the summer breeding season depended on the degree of follicular activity. Mares with inactive ovaries and small follicles failed to respond with normal cycles post-treatment, whereas a higher proportion of mares with ovarian follicles 20 mm or greater in diameter exhibited normal estrus cycles post-treatment. Regu-Mate (altrenogest) Solution 0.22% was very effective for suppressing the prolonged estrus behavior frequently observed in mares during the transition period (February, March and April). In addition, a high proportion of these mares responded with regular estrus cycles post-treatment.

SPECIFIC USES FOR REGU-MATE (altrenogest) SOLUTION 0.22%:

SUPPRESSION OF ESTRUS TO:

1. Facilitate attainment of regular cycles during the transition period from winter anestrus to the physiological breeding season.

To facilitate attainment of regular cycles during the transition phase, mares should be examined to determine the degree of ovarian activity. Estrus in mares with inactive ovaries (no follicles greater than 20 mm in diameter) will be suppressed but these mares may not begin regular cycles following treatment. However, mares with active ovaries (follicles greater than 20 mm in diameter) frequently respond with regular post-treatment estrus cycles.

2. Facilitate management of the mare exhibiting prolonged estrus during the transition period. Estrus will be suppressed in mares exhibiting prolonged behavioral estrus either early or late during the transition period. Again, the post-treatment response depends on the level of ovarian activity. The mares with greater ovarian activity initiate regular cycles and conceive sooner than the inactive mares. Regu-Mate (altrenogest) Solution 0.22% may be administered early in the transition period to suppress estrus in mares with inactive ovaries to aid in the management of these mares or to mares later in the transition period with active ovaries to prepare and schedule the mare for breeding.

3. Permit scheduled breeding of mares during the physiological breeding season. To permit scheduled breeding, mares which are regularly cycling or which have active ovarian function should be given Regu-Mate Solution 0.22% daily for 15 consecutive days beginning 20 days before the date of the planned estrus.

Ovulation will occur 5 to 7 days following the onset of estrus as expected for non-treated mares. Breeding should follow usual procedures for mares in estrus. Mares may be regulated and scheduled either individually or in groups.

Warning: Do not use in horses intended for food.

Caution For Handlers:

Skin contact must be avoided as Regu-Mate (altrenogest) Solution 0.22% is readily absorbed through unbroken skin. Protective gloves must be worn by all persons handling this product. Pregnant women or women who suspect they are pregnant should not handle Regu-Mate (altrenogest) Solution 0.22%. Women of child bearing age should exercise extreme caution when handling this product. Accidental absorption could lead to a disruption of the menstrual cycle or prolongation of pregnancy. Direct contact with the skin should therefore be avoided. Accidental spillage on the skin should be washed off immediately with soap and water.

Regu-Mate (altrenogest) Solution 0.22% is readily absorbed by the skin. Skin contact must be avoided; protective gloves must be worn when handling this product.

Effects of Overexposure

There has been no human use of this specific product. The information contained in this section is extrapolated from data available on other products of the same pharmacological class that have been used in humans. Effects anticipated are due to the progestational activity of altrenogest.

Acute effects after a single exposure are possible; however, continued daily exposure has the potential for more untoward effects such as disruption of the menstrual cycle, uterine or abdominal cramping, increased or decreased uterine bleeding, prolongation of pregnancy and headaches. The oil base may also cause complications if swallowed.

In addition, the list of people who should not handle this product (see below) is based upon the known effects of progestins used in humans on a chronic basis.

People Who Should Not Handle This Product:

1. Women who are or suspect they are pregnant.

2. Anyone with thrombophlebitis or thromboembolic disorders or with a history of these events.

3. Anyone with cerebral-vascular or coronary-artery disease.

4. Women with known or suspected carcinoma of the breast.

5. People with known or suspected estrogen-dependent neoplasia.

6. Women with undiagnosed vaginal bleeding.

7. People with benign or malignant tumors which developed during the use of oral contraceptives or other estrogen-containing products.

8. Anyone with liver dysfunction or disease.

Accidental Exposure

Altrenogest is readily absorbed from contact with the skin. In addition, this oil based product can penetrate porous gloves. Altrenogest should not penetrate intact rubber or impervious gloves; however, if there is leakage (i.e., pinhole, spillage, etc.), the contaminated area covered by such occlusive materials may have increased absorption. The following measures are recommended in case of accidental exposure.

Skin Exposure: Wash immediately with soap and water.

Eye Exposure: Immediately flush with plenty of water for 15 minutes. Get medical attention.

If Swallowed: Do not induce vomiting. Regu-Mate (altrenogest) Solution 0.22% contains an oil. Call a physician. Vomiting should be supervised by a physician because of possible pulmonary damage via aspiration of the oil base. If possible bring the container and labeling to the physician.

CAUTION: For oral use in horses only. Keep this and all medication out of the reach of children.

Federal law restricts this drug to use by or on the order of a licensed veterinarian

Store at room temperature.

Rx Medication Sold Only To Licensed Veterinarians & Pharmacies. Current License Must Be On File Prior To Shipping.


Share your knowledge of this product. Be the first to write a review »
69142 Highway 59, Suite E, Mandeville, Louisiana 70471
Medi-Vet offers pet medications including Comfortis, Rimadyl, Deramaxx, Metacam, Heartgard, Interceptor, Sentinel, Frontline Plus, Frontline Top Spot, Advantage, K9 Advantix and other Flea and Tick products. Medi-Vet also offers ringworm medications, pet meds, vet supplies, heartworm prevention, grooming supplies, flea and tick control, pet medicine, Frontline Topspot, horse care supplies, horse medication, dog shampoos, canine vaccines, and prescription medications for pet and animal health. Medi-Vet.com is a wholesale drug distributor for veterinarians, pharmacies and drug companies.